Hormone receptor positive HER2 negative breast cancer

• EORTC 2237-BCG-QLG: Improvement of Quality of Life through supportive treatments for Endocrine Therapy – related symptoms in patients with e … Not authorised
  2024-513442-10-00 5 "ER positive HER2 negative breast cancer stages I-II"
• Clinical trial evaluating the biological activity of a new drug identified as prifetrastat (PF-07248144), combined with fulvestrant for the … Pending
  2025-521982-29-00 4 "Adult patients with advanced hormone receptor positive (HR+)"
• Study of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid … Recruiting
  2025-521911-38-00 7 2026-05-26 "Advanced HR+/HER- breast cancer"
• The combination of Elacestrant and exemestane for patients with pretreated metastatic breast cancer expressing hormone receptors and non-exp … Recruiting
  2024-519792-25-00 4 2026-05-11 "Metastatic hormone receptor-positive/HER2-negative breast ca"
• An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Rec … Recruiting
  2025-520582-51-00 5 2025-10-17 "Hormone receptor positive breast cancer"
• A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications Recruiting
  2023-506227-29-00 3 2024-08-30 "locally advanced or metastatic solid tumors"
• A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of BG-75202, … Recruiting
  2025-523553-34-00 1 2026-04-15 "Advanced and Metastatic Solid tumors"
• A Phase 1, First-in-Human Study of MEN2312, a KAT6 inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer Recruiting
  2024-514661-19-01 1 2026-02-18 "Advanced ER+/HER2- Breast Cancer"
• A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity … Recruiting
  2025-523165-19-00 1 2026-02-10 "Advanced, metastatic or unresectable solid tumors"
• A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg … Recruiting
  2025-523083-21-00 5 2025-12-08 "PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Gro"
• A clinical study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside routine endocrine treatment in pa … Recruiting
  2024-511392-15-00 5 2025-11-20 "HR+/HER2- advanced breast cancer"
• Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors Recruiting
  2024-517281-42-00 7 2025-11-12 "Advanced solid tumors"
• A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advan … Recruiting
  2025-520566-22-00 5 2025-11-10 "Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic"
• TYPER Recruiting
  2024-520290-12-00 6 2025-11-04 "Hormone receptor–positive (HRpos)/human epidermal growth fac"
• A clinical study of patritumab deruxtecan in people with breast cancer Recruiting
  2024-514376-40-00 4 2025-10-15 "High Risk Early-Stage Triple Negative Breast Cancer (TNBC) o"
• ABCSG 63 / ERIKA: Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer: An open-label, two-arm, randomized, phase I … Recruiting
  2023-505758-17-00 4 2025-08-21 "endocrine-responsive HER2-negative early breast cancer"
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 "Node-positive, Estrogen Receptor-positive, HER2-negative, Ea"
• Pan-tumor Study of I-DXd in Subjects with Recurrent or Metastatic Solid Tumors Recruiting
  2023-509632-26-00 9 2025-02-11 "Recurrent or Metastatic Solid Tumors (endometrial cancer (EC"
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CD … Recruiting
  2023-506888-34-00 1 2024-05-22 "Advanced or metastatic solid tumors including hormone recept"
• A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety,Tolerability, Pharmacoki … Recruiting
  2023-507738-26-00 9 2024-03-20 "Breast Cancer"
• An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi … Recruiting
  2022-501453-36-00 5 2024-02-23 "Breast cancer"
• CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE … Recruiting
  2022-500764-35-00 6 2022-10-13 "Patients with advanced HER2-negative, hormone receptor posit"
• A trial to learn more about the effects of ribociclib taken with endocrine therapy in patients with early breast cancer. Recruitment ended
  2022-503001-38-01 5 2025-07-08 "HR-positive HER-2- negative Breast Cancer"
• Study of Zelenectide Pevedotin in Participants with Advanced Breast Cancer Recruitment ended
  2024-517868-33-00 4 2025-06-12 "NECTIN4 Amplified Advanced Breast Cancer"

Showing 1–24 of 37 trials